The Higher Expression of CDCA2 Associated with Poor Prognosis in Glioma

Abstract

Glioma is the most common primary intracranial tumor and is related to poor clinical outcomes. The developments of sensitive markers can be applied to reveal the mechanisms involved in the progression of glioma. This study examined CDCA2 expression in glioma samples and its significance in predicting glioma patient outcome. GEPIA and GEO datasets were used to explore the expression of CDCA2 in glioma. Kaplan-Meier and multivariate assays were applied to delve into the prognostic values of CDCA2 expression in glioma patients using CGGA datasets. Our group also determined the associations between CDCA2 and clinical characteristics. Coexpression analysis was performed. In this research, we observed that CDCA2 expression was distinctly upregulated in glioma specimens compared with nontumor specimens. The prognosis of glioma with high CDCA2 expression was distinctly worse compared with that of glioma with low CDCA2 expression. Additionally, multivariate Cox regression analysis revealed that high CDCA2 expression was an independent poor prognostic indicator for glioma patients. High expression of CDCA2 was positively associated with advanced clinical progression. Coexpression analysis revealed that CDCA2 could be positively related to ASPM, SKA1, DLGAP5, NCAPG, and CDCA8 and was negatively associated with ETNPPL, LDHD, MRVI1, CBX7, and CENPJ. Overall, our findings revealed that CDCA2 might serve as an independent prognosis indicator for glioma.

Novel Functional Features of cGMP Substrate Proteins IRAG1 and IRAG2

“…Furthermore, the gene expression of IRAG1 was upregulated in the context of pancreatic ductal adenocarcinoma (PDAC) after silencing the transcription factor basic transcription factor 3 (BTF3) in pancreatic cancer cell lines [ 46 ]. Additionally, expression of IRAG1 was negatively associated with high expression of the cell division cycle-associated protein 2 (CDCA2) in glioma [ 47 ].…”

A mini-review of the role of condensin in human nervous system diseases

“…Currently, studies have shown that the subunits of condensin, such as NCAPG, SMC4, and NCAPG2, have been reported to be involved in the glioma pathogenesis. Wherein, NCAPG could be positively related to CDCA2 (cell division cycle-associated protein 2) in glioma, and the over-expression of NCAPG may regulate the cell cycle and promote the proliferation, migration, and invasion of glioma cells (Liang et al, 2016 ; Jiang et al, 2022 ; Jin et al, 2022 ). Meanwhile, NCAPG overexpression can also increase the expression of MHCI and AMAD17 molecules, both of which are located on the tumor surface, thus, assisting in camouflaging the tumor and preventing NK cells from being activated in the immune microenvironment (Zheng et al, 2022 ).…”

ANXA5 promotes glioma progression through the FAk/PI3K/AKT pathway

“…From 2016, when the World Health Organization combined histopathology and molecular features for the rst time in the classi cation of central nervous system tumors, to 2021, the classi cation of glioma was continuously modi ed according to histopathology and molecular features, marking an important shift in glioma classi cation [19]. More and more researches focus on molecular biomarkers to aid in glioma diagnosis and treatment [20,21]. ANXA5 is an annexin with high a nity for phosphatidylserine through calcium ion.…”